Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to Dienogest for people with endometriosis.

The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based guidance for the National Health Service in England on best practice. In its guideline on the diagnosis and management of endometriosis, last updated in November 2024, NICE recommends that hormonal treatment such as Dienogest should be offered to women with suspected, confirmed or recurrent endometriosis.

It is the clinician’s responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. Prescribers must always satisfy themselves that the medicines they consider appropriate for their patients can be safely prescribed and ensure that they take account of NICE guidelines, as well as the local commissioning decisions of their respective integrated care boards.